Dorzolamide Hydrochloride and Timolol Maleate Ophthalmic Solution, 2%/0.5% (preservative free) is indicated for reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers. This solution combines dorzolamide hydrochloride, an inhibitor of human carbonic anhydrase II, with timolol maleate, a beta 1 and beta 2 (non-selective) adrenergic receptor blocking agent. Both components reduce IOP by decreasing aqueous humor secretion.
Key Clinical Findings
The IOP-lowering effect of the solution administered twice daily was less than that of timolol administered twice daily and dorzolamide administered three times daily. The IOP lowering effect of the solution was approximately 1 mmHg less than that of concomitant therapy with dorzolamide administered three times daily and timolol twice daily. The solution’s IOP-lowering effect was consistent during a 12-month follow-up period.